## Preferred Product Characteristics for Personal Protective Equipment for the Health Worker on the Frontline Responding to Viral Hemorrhagic Fevers in Tropical Climates





Preferred Product Characteristics for Personal Protective Equipment for the Health Worker on the Frontline Responding to Viral Hemorrhagic Fevers\* in Tropical Climates



\*Ebola, Marburg and other hemorrhagic fevers that share similar human-to-human transmission characteristics

Preferred product characteristics for personal protective equipment for the health worker on the frontline responding to viral hemorrhagic fevers in tropical climates ISBN 978-92-4-151415-6

#### © World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <u>https://creativecommons.org/licenses/by-nc-sa/3.0/igo</u>). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation:

"This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition". Any mediation relating to dispute arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation**. Preferred product characteristics for personal protective equipment for the health worker on the frontline responding to viral hemorrhagic fevers in tropical climates. Geneva: World Health Organization; 2018. Licence: <u>CC BY-NC-SA 3.0 IGO</u>.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

**Sales, rights and licensing.** To purchase WHO publications, see <u>http://apps.who.int/bookorders</u>. To submit requests for commercial use and queries on rights and licensing, see <u>http://www.who.int/about/licensing</u>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

> This document was produced jointly by: Medical Devices, Innovation Access and Use Unit Essential Medicines and Health Products Department Access to Medicines, Vaccines and Pharmaceuticals and Experts Networks-Clinical Management Infectious Hazards Management Department Health Emergencies

For more information about this document, please contact: World Health Organization 20 Avenue Appia; 1211 Geneva 27, Switzerland Email: techinnovation@who.int or medicaldevices@who.int

Printed by the WHO Document Production Services, Geneva, Switzerland

## Table of contents

ACk	NOWLEDGEMENTS	L
Acr	ONYMS	L
DEF	INITIONS	2
INT	ENDED TARGET	}
1.	BACKGROUND	ļ
2.	SCOPE	5
3.	AIM	5
4.	OBJECTIVES	5
5.	METHODOLOGY	5
6.	PREFERRED PRODUCT CHARACTERISTICS	7
6.1 6.2	DESIGN FEATURES	
7.	UNMET NEEDS	3
7.1. 7.2. 7.3. 7.4.	TRANSMISSIBILITY OF EBOLA, MARBURG AND OTHER DISEASES WITH THAT SHARE SIMILAR TRANSMISSION   CHARACTERISTICS NEED FURTHER ELUCIDATION   TESTING AND STANDARD DEVELOPMENT	3
8.	DESIRED OUTCOME USING THIS GUIDANCE	)
8.1. 8.2.	ENGAGING STAKEHOLDERS	
APF	ENDIX 1. ADVISORY COMMITTEE FOR INNOVATIVE PPE( AC) MEMBERS AND WHO SECRETARIAT 20	)
AD۱	/ISORY COMMITTEE SECRETARIAT	}
APF	ENDIX 2. TECHNICAL SPECIFICATIONS AND PERFORMANCE STANDARDS FOR PPE	ļ
APF	ENDIX 3 FIGURE 1: TECHNICAL SPECIFICATIONS AND PERFORMANCE CHARACTERISTICS	5
TAE	LE 3. TECHNICAL SPECIFICATIONS AND PERFORMANCE STANDARDS	5

### **Acknowledgements**

This document is the product of technical information and guidance received from subject matter experts, field health workers, administrators and regulatory bodies. Many individuals shared knowledge and expertise, through workshops, conferences and solicited comments. Input was also received from the open consultation period. The WHO Advisory Committee for Innovative Personal Protective Equipment (AC) consisted of four sub groups. AC members, their affiliations and committee subgroup, as well as the WHO staff who provided critical leadership and expertise, are listed in Appendix 1.

WHO thanks the government of Japan and the U.S. Agency for International Development for their contribution to this effort.

#### Acronyms

AAMI AATCC AC AC-WG ANSI ASTM BS EN DIN EN EBOV EN	Association of the Advancement of Medical Instrumentation American Association of Textile Chemists and Colorists WHO Advisory Committees for Innovative Personal Protective Equipment WG AC working group American National Standards Institute American Society of Testing Materials International European Standard that is published in United Kingdom European Standard is published in Germany by German Standards Institute Ebola virus
ETU	Ebola treatment unit
EVD	Ebola virus disease
HW	Health worker
HW-F	Health worker at the frontline
IPC	Infection prevention and control
ISO	International Organization for Standardization
MSF	Médecins sans Frontières (Doctors without Borders)
N95	Respirator, blocks at least 95% of 0.3 micron test particles
NFPA	National Fire Protection Association
OSH	Occupational safety and health
PAPR	Powered air purifying respirator
PPE	Personal protective equipment
PPC	Preferred product characteristics
R&D	Research and development
RSV	Respiratory Syncytial Virus
SARS	Severe Acute Respiratory Syndrome
ТРР	Target product profile
WHO	World Health Organization

#### **Definitions**

Health worker at the frontline (HW-F): Clinical health workers tending to Ebola virus disease (EVD) patients and non-clinical staff performing heavy duty services such as transporting symptomatic patients, care-setting cleaning, environment decontamination and removal of deceased for respectful disposition. Together, these workers are at the highest risk of exposure and thus are defined as health workers at the frontline (HW-F). Health worker (HW) is a more generalized term for those personnel who also will use PPE but are not necessarily in direct patient contact or performing high risk activities.

*Ebola treatment unit (ETU)s*: Treatment units set up for EVD patients, with sections divided into increasing degree of illness from triage to suspect (holding) to confirmed zones (treatment).

Low and middle income countries: As defined using the World Bank country classification.

*Preferred product characteristics (PPC)*: A PPC profile describes the preferred criteria for a product or suite of products that meet the intended unmet public health need in a priority disease area and is structured to drive innovation towards meeting the need. PPC addresses research and development (R&D) therefore its parameters are not static and will be reviewed and updated periodically to meet the public health demand.

*Standard precautions*: Set of infection control practices used to prevent transmission of diseases and should be applied in a constant basis with all patients, regardless of diagnosis- in all practices and at all times. Standard precautions include: hand hygiene, use of PPE based on risk assessment, prevention of needle-stick or sharps injuries, safe waste management, cleaning, disinfection and sterilization; where applicable, of the equipment, linen used and the patient care environment. This is to protect from contact with blood, body fluids, non-intact skin (including rashes), and mucous membranes.

*Target product profile (TPP)*: May contain similar parameters as PPC and includes a set of desired minimally acceptable technical specifications in addition to preferred criteria. TPP is a technical document detailing specific requirements.

*Technical specifications*: Refers to the existing local, national, regional and international sets of standards, testing methods and quality control systems for which all individual PPE elements are reviewed or tested before they can be made available in their respective markets. The manufacturers and normative entities take the responsibility to ensure product performance and reliability. Detailed explanations are in Figure 1 in Appendix 3.

*Tropical climate*: Tropical zones dominated by abundant rainfall with a temperature range of >200 C-380 C and >75-95% humidity. This includes tropical rainforest, monsoon and savanna climate zones (i.e. "hot, humid" conditions).

*Work period*: Little is known about the ideal amount of time a HW-F can wear PPE and safely provide care for a patient or carry out heavy duty work. This period includes the time needed for donning and doffing PPE. The literature indicates that given existing knowledge about disease transmission, an appropriate period may be between 40 minutes and 4 hours. Beyond this time, the HW-F may become subject to discomfort and be more likely to misuse PPE, thereby increasing the chance of disease transmission. For this reason, we define a work period as being between 40 minutes and 4 hours, subject to IPC protocol.

#### **Intended target**

Key explanations and concepts are presented here to guide the reader when viewing this document.

Intended target for this PPC document: Although this document is addressing the unmet public health need for protective PPE for the HW-F when responding to Ebola virus (EBOV) infections, the principles of this guidance may also be applied to other filovirus infections such as Marburg virus. The document may also have applications for other diseases that share human-to-human transmission characteristics which pose a similar risk to the health worker (see explanation in *Definitions*) (Table 1).

Target population, setting and use		
Primary target use population	Heath workers on the frontline providing patient care and heavy duty	
	services in basic facilities under hot, humid conditions.	
Secondary target use population	Health workers who will use PPE for protection from high risk exposure in	
	advanced equipped medical facilities.	
Target use setting	Health facilities and community environments where health workers on	
	the frontline are at risk of exposure to virus shedding by patients or dead	
	bodies.	
Intended use	To serve as a guide for health workers, industry, engineers, innovators, medical and scientific researchers and others, the opportunity to re-think, energize and innovate for a better PPE system to protect the health worker.	

#### Table 1. The target use populations, setting and intended use of this PPC document

*Use of evidence from Severe Acute Respiratory Syndrome (SARS) and Respiratory Syncytial Virus (RSV) studies*: This document focuses on evidence research from EBOV publications combined with generalized information from SARS and RSV infections studies. SARS and RSV can be transmitted through mucous membrane contacts via airborne or aerosolized virus. EVD is primarily transmitted through contact of infectious virus with mucous membranes. EBOV has not been proven to be transmitted by aerosol, despite animal studies designed to study this route<sup>1,2</sup>.

*Technical specifications* for PPE are comprised of a complex set of product characteristics, standards and methods with most of the specifications applying to an individual PPE element or category (Figure 1, Appendix 3), which are used for procurement. Many of the existing standards apply to conditions relevant to the characteristics described in this document but none specifically addresses a *full PPE* 

# 预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 25596